1
|
Prasad Raiguru B, Panda J, Mohapatra S, Nayak S. Recent developments in the synthesis of hybrid antimalarial drug discovery. Bioorg Chem 2023; 139:106706. [PMID: 37406519 DOI: 10.1016/j.bioorg.2023.106706] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 05/16/2023] [Accepted: 06/26/2023] [Indexed: 07/07/2023]
Abstract
In this 21st century, Malaria remains a global burden and causes massive economic trouble to disease-endemic nations. The control and eradication of malaria is a major challenge that requires an urgent need to develop novel antimalarial drugs. To overcome the aforementioned situation, several researchers have given significant effort to develop hybrid antimalarial agents in the search for new antimalarial drugs. Hence, we have summarized those developments of hybrid antimalarial agents from 2017 to till date. This review illustrates the current progress in the recent synthesis of hybrid antimalarial agents along with focusing on their antimalarial evaluation to find the most potent hybrids. This present mini-review will also be useful for the scientific community for the development of new antimalarial drugs to eradicate malaria.
Collapse
Affiliation(s)
| | - Jasmine Panda
- Department of Chemistry, Ravenshaw University, Cuttack 753003, India
| | | | - Sabita Nayak
- Department of Chemistry, Ravenshaw University, Cuttack 753003, India
| |
Collapse
|
2
|
Haroon F, Farwa U, Arif M, Raza MA, Sandhu ZA, El Oirdi M, Farhan M, Alhasawi MAI. Novel Para-Aminobenzoic Acid Analogs and Their Potential Therapeutic Applications. Biomedicines 2023; 11:2686. [PMID: 37893060 PMCID: PMC10604881 DOI: 10.3390/biomedicines11102686] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2023] [Revised: 09/23/2023] [Accepted: 09/26/2023] [Indexed: 10/29/2023] Open
Abstract
A "building block" is a key component that plays a substantial and critical function in the pharmaceutical research and development industry. Given its structural versatility and ability to undergo substitutions at both the amino and carboxyl groups, para-aminobenzoic acid (PABA) is a commonly used building block in pharmaceuticals. Therefore, it is great for the development of a wide range of novel molecules with potential medical applications. Anticancer, anti-Alzheimer's, antibacterial, antiviral, antioxidant, and anti-inflammatory properties have been observed in PABA compounds, suggesting their potential as therapeutic agents in future clinical trials. PABA-based therapeutic chemicals as molecular targets and their usage in biological processes are the primary focus of this review study. PABA's unique features make it a strong candidate for inclusion in a massive chemical database of molecules having drug-like effects. Based on the current literature, further investigation is needed to evaluate the safety and efficacy of PABA derivatives in clinical investigations and better understand the specific mechanism of action revealed by these compounds.
Collapse
Affiliation(s)
- Faisal Haroon
- Department of Basic Sciences, Preparatory Year Deanship, King Faisal University, Al-Ahsa 31982, Saudi Arabia; (M.E.O.); (M.F.)
| | - Umme Farwa
- Department of Chemistry, Hafiz Hayat Campus, University of Gujrat, Gujrat 50700, Pakistan; (U.F.); (M.A.); (Z.A.S.)
| | - Maimoona Arif
- Department of Chemistry, Hafiz Hayat Campus, University of Gujrat, Gujrat 50700, Pakistan; (U.F.); (M.A.); (Z.A.S.)
| | - Muhammad Asam Raza
- Department of Chemistry, Hafiz Hayat Campus, University of Gujrat, Gujrat 50700, Pakistan; (U.F.); (M.A.); (Z.A.S.)
| | - Zeshan Ali Sandhu
- Department of Chemistry, Hafiz Hayat Campus, University of Gujrat, Gujrat 50700, Pakistan; (U.F.); (M.A.); (Z.A.S.)
| | - Mohamed El Oirdi
- Department of Basic Sciences, Preparatory Year Deanship, King Faisal University, Al-Ahsa 31982, Saudi Arabia; (M.E.O.); (M.F.)
| | - Mohd Farhan
- Department of Basic Sciences, Preparatory Year Deanship, King Faisal University, Al-Ahsa 31982, Saudi Arabia; (M.E.O.); (M.F.)
| | | |
Collapse
|
3
|
Adhikari N, Choudhury AAK, Shakya A, Ghosh SK, Patgiri SJ, Singh UP, Bhat HR. Design and development of novel
N
‐(4‐aminobenzoyl)‐
l
‐glutamic acid conjugated 1,3,5‐triazine derivatives as
Pf
‐DHFR inhibitor: An
in‐silico
and
in‐vitro
study. J Biochem Mol Toxicol 2022; 37:e23290. [PMID: 36541419 DOI: 10.1002/jbt.23290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Revised: 10/17/2022] [Accepted: 12/09/2022] [Indexed: 12/24/2022]
Abstract
In the present work, a library of 120 compounds was prepared using various aliphatic and aromatic amines. Finally, 10 compounds were selected through in silico screening carrying 4-aminobenzoyl-l-glutamic acid and 1,3,5-triazine moiety. The docking results of compounds 4d16 and 4d38 revealed higher binding interaction with amino acids Asp54 (-537.96 kcal/mol) and Asp54, Phe116 (-618.22 kcal/mol) against wild (1J3I) and quadruple mutant (1J3K) type of Pf-DHFR inhibitors and were comparable to standard WR99210. These compounds were developed by facile and microwave-assisted synthesis via nucleophilic substitution reaction and characterized by different spectroscopic methods. In vitro antimalarial assay results also suggested that these two compounds were having higher antimalarial activity against chloroquine-sensitive (3D7) and chloroquine-resistant (Dd2) strain out of the ten synthesized compounds with IC50 13.25 μM and 14.72 μM, respectively. These hybrid scaffolds might be useful in the lead discovery of a new class of Pf-DHFR inhibitors.
Collapse
Affiliation(s)
- Nayana Adhikari
- Department of Pharmaceutical Sciences Dibrugarh University Dibrugarh Assam India
| | | | - Anshul Shakya
- Department of Pharmaceutical Sciences Dibrugarh University Dibrugarh Assam India
| | - Surajit K. Ghosh
- Department of Pharmaceutical Sciences Dibrugarh University Dibrugarh Assam India
| | - Saurav J. Patgiri
- Regional Medical Research Centre, Indian Council of Medical Research (ICMR) Dibrugarh Assam India
| | - Udaya P. Singh
- Drug Design & Discovery Laboratory, Department of Pharmaceutical Sciences Sam Higginbottom University of Agriculture, Technology & Sciences Prayagraj Uttar Pradesh India
| | - Hans R. Bhat
- Department of Pharmaceutical Sciences Dibrugarh University Dibrugarh Assam India
| |
Collapse
|
4
|
Adhikari N, Choudhury AAK, Shakya A, Ghosh SK, Patgiri SJ, Singh UP, Bhat HR. Molecular docking and antimalarial evaluation of novel N-(4-aminobenzoyl)-l-glutamic acid conjugated 1,3,5-triazine derivatives as Pf-DHFR inhibitors. 3 Biotech 2022; 12:347. [PMID: 36386564 PMCID: PMC9649585 DOI: 10.1007/s13205-022-03400-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2022] [Accepted: 10/12/2022] [Indexed: 11/12/2022] Open
Abstract
Malaria has been a source of concern for humans for millennia; therefore in the present study we have utilized in-silico approach to generate diverse anti-malarial hit. Towards this, Molinspiration cheminformatics and Biovia Discovery Studio (DS) 2020 were used to conduct molecular modelling studies on 120 designed compounds. Furthermore, the TOPKAT module was used to evaluate the toxicity of the screened compounds. The CDOCKER docking technology was used to investigate protein-ligand docking against the Pf-DHFR-TS protein (PDB ID: 1J3I and 1J3K). These compounds were synthesized using a conventional and microwave-assisted nucleophilic substitution reaction, and they were characterized using a variety of physicochemical and spectroscopic methods. Among the ten compounds tested, Df3 had the highest antimalarial activity against the chloroquine-resistant (Dd2) strain, with an IC50 value of 9.54 μg mL-1 and further demonstrate, molecular dynamics (MD) simulation studies and estimation of MM-PBSA-based free binding energies of docked complexes with 1J3I and 1J3K were carried out. The discovery of a novel class of Pf-DHFR inhibitors can be accomplished using this hybrid scaffold. Supplementary Information The online version contains supplementary material available at 10.1007/s13205-022-03400-2.
Collapse
Affiliation(s)
- Nayana Adhikari
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam 786004 India
| | | | - Anshul Shakya
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam 786004 India
| | - Surajit Kumar Ghosh
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam 786004 India
| | - Saurav Jyoti Patgiri
- Regional Medical Research Centre, Indian Council of Medical Research (ICMR), Dibrugarh, Assam 786001 India
| | - Udaya Pratap Singh
- Drug Design and Discovery Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology and Sciences, Allahabad, Uttar Pradesh 211007 India
| | - Hans Raj Bhat
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam 786004 India
| |
Collapse
|
5
|
Shawish I, Nafie MS, Barakat A, Aldalbahi A, Al-Rasheed HH, Ali M, Alshaer W, Al Zoubi M, Al Ayoubi S, De la Torre BG, Albericio F, El-Faham A. Pyrazolyl-s-triazine with indole motif as a novel of epidermal growth factor receptor/cyclin-dependent kinase 2 dual inhibitors. Front Chem 2022; 10:1078163. [PMID: 36505739 PMCID: PMC9732672 DOI: 10.3389/fchem.2022.1078163] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Accepted: 11/10/2022] [Indexed: 11/26/2022] Open
Abstract
A series of pyrazolyl-s-triazine compounds with an indole motif was designed, synthesized, and evaluated for anticancer activity targeting dual EGFR and CDK-2 inhibitors. The compounds were tested for cytotoxicity using the MTT assay. Compounds 3h, 3i, and 3j showed promising cytotoxic activity against two cancer cell lines, namely A549, MCF-7, and HDFs (non-cancerous human dermal fibroblasts). Compound 3j was the most active candidate against A549, with an IC50 of 2.32 ± 0.21 μM. Compounds 3h and 3i were found to be the most active hybrids against MCF-7 and HDFs, with an IC50 of 2.66 ± 0.26 μM and 3.78 ± 0.55 μM, respectively. Interestingly, 3i showed potent EGFR inhibition, with an IC50 of 34.1 nM compared to Erlotinib (IC50 = 67.3 nM). At 10 μM, this candidate caused 93.6% and 91.4% of EGFR and CDK-2 inhibition, respectively. Furthermore, 3i enhanced total lung cancer cell apoptosis 71.6-fold (43.7% compared to 0.61% for the control). Given the potent cytotoxicity exerted by 3i through apoptosis-mediated activity, this compound emerges as a promising target-oriented anticancer agent.
Collapse
Affiliation(s)
- Ihab Shawish
- Department of Math and Sciences, College of Humanities and Sciences, Prince Sultan University, Riyadh, Saudi Arabia,Department of Chemistry, College of Science, King Saud University, Riyadh, Saudi Arabia
| | - Mohamed S. Nafie
- Department of Chemistry, Faculty of Science, Suez Canal University, Ismaïlia, Egypt
| | - Assem Barakat
- Department of Chemistry, College of Science, King Saud University, Riyadh, Saudi Arabia,*Correspondence: Assem Barakat, ; Fernando Albericio, ; Ayman El-Faham,
| | - Ali Aldalbahi
- Department of Chemistry, College of Science, King Saud University, Riyadh, Saudi Arabia
| | - Hessa H. Al-Rasheed
- Department of Chemistry, College of Science, King Saud University, Riyadh, Saudi Arabia
| | - M. Ali
- Department of Chemistry, College of Science, King Saud University, Riyadh, Saudi Arabia
| | - Walhan Alshaer
- Cell Therapy Center, The University of Jordan, Amman, Jordan
| | - Mazhar Al Zoubi
- Department of Basic Medical Sciences, Faculty of Sciences, Yarmouk University, Irbid, Jordan
| | - Samha Al Ayoubi
- Department of Math and Sciences, College of Humanities and Sciences, Prince Sultan University, Riyadh, Saudi Arabia
| | - Beatriz G. De la Torre
- KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP) School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa,Peptide Science Laboratory, School of Chemistry and Physics, University of KwaZulu-Natal, Durban, South Africa
| | - Fernando Albericio
- Peptide Science Laboratory, School of Chemistry and Physics, University of KwaZulu-Natal, Durban, South Africa,CIBER-BBN (Networking Centre on Bioengineering, Biomaterials and Nanomedicine) and Department of Organic Chemistry, University of Barcelona, Barcelona, Spain,*Correspondence: Assem Barakat, ; Fernando Albericio, ; Ayman El-Faham,
| | - Ayman El-Faham
- Chemistry Department, Faculty of Science, Alexandria University, Alexandria, Egypt,*Correspondence: Assem Barakat, ; Fernando Albericio, ; Ayman El-Faham,
| |
Collapse
|
6
|
Microwave synthesis and antimalarial screening of novel 4-amino benzoic acid (PABA)-substituted pyrimidine derivatives as Plasmodium falciparum dihydrofolate reductase inhibitors. 3 Biotech 2022; 12:170. [PMID: 35845109 PMCID: PMC9279537 DOI: 10.1007/s13205-022-03236-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2022] [Accepted: 06/18/2022] [Indexed: 11/28/2022] Open
Abstract
Antimalarial drug resistance is a major threat due to the emerging resistance to all the available drugs in the market. In an approach to develop alternative drugs, a novel class of Pf-DHFR inhibitors was developed using pyrimidine as the core nucleus and substituting the 4- and 6- positions with amines and 4-amino benzoic acid (PABA) to avoid the problem of drug resistance. The resultant compounds 3(a-j) after primary in silico screening and filtering were synthesized using microwave efficiently in high yield and reduced time period compared to conventional synthesis. The antimalarial assay was performed in vitro, against chloroquine-sensitive (3D7) and chloroquine-resistant (Dd2) strains of Plasmodium falciparum using chloroquine as a reference standard. The IC50 values were in the range of 5.26-106.76 µg/ml for 3D7 and in Dd2 the value ranges from 4.71 to 112.98 µg/ml. Compounds 3d, 3e, 3f and 3h showed significant antimalarial activity against both the strains of P. falciparum with no cytotoxicity against fibroblast cell line and 3f was found to be the most potent among them. The hemolysis assay of all the compounds in fresh erythrocytes showed insignificant hemolysis below 5% at a higher dose level. Hence, the present study suggests the possible utility of PABA-substituted pyrimidine scaffold for further development of new Pf-DHFR inhibitors. Supplementary Information The online version contains supplementary material available at 10.1007/s13205-022-03236-w.
Collapse
|
7
|
Shawish I, Barakat A, Aldalbahi A, Malebari AM, Nafie MS, Bekhit AA, Albohy A, Khan A, Ul-Haq Z, Haukka M, de la Torre BG, Albericio F, El-Faham A. Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)- s-triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades. ACS OMEGA 2022; 7:24858-24870. [PMID: 35874229 PMCID: PMC9301957 DOI: 10.1021/acsomega.2c03079] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Here, we synthesized a newseries of mono- and bis(dimethylpyrazolyl)-s-triazine derivatives. The synthetic methodology involved the reaction of different mono- and dihydrazinyl-s-triazine derivatives with acetylacetone in the presence of triethylamine to produce the corresponding target products in high yield and purity. The antiproliferative activity of the novel mono- and bis(dimethylpyrazolyl)-s-triazine derivatives was studied against three cancer cell lines, namely, MCF-7, HCT-116, and HepG2. N-(4-Bromophenyl)-4-(3,5-dimethyl-1H-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine 4f, N-(4-chlorophenyl)-4,6-bis(3,5-dimethyl-1H-pyrazol-1-yl)-1,3,5-triazin-2-amine 5c, and 4,6-bis(3,5-dimethyl-1H-pyrazol-1-yl)-N-(4-methoxyphenyl)-1,3,5-triazin-2-amine 5d showed promising activity against these cancer cells: 4f [(IC50 = 4.53 ± 0.30 μM (MCF-7); 0.50 ± 0.080 μM (HCT-116); and 3.01 ± 0.49 μM (HepG2)]; 5d [(IC50 = 3.66 ± 0.96 μM (HCT-116); and 5.42 ± 0.82 μM (HepG2)]; and 5c [(IC50 = 2.29 ± 0.92 μM (MCF-7)]. Molecular docking studies revealed good binding affinity with the receptor targeting EGFR/PI3K/AKT/mTOR signaling cascades. Compound 4f exhibited potent EGFR inhibitory activity with an IC50 value of 61 nM compared to that of Tamoxifen (IC50 value of 69 nM), with EGFR inhibition of 83 and 84%, respectively, at a concentration of 10 μM. Interestingly, 4f showed remarkable PI3K/AKT/mTOR inhibitory activity with 0.18-, 0.27-, and 0.39-fold decrease in their concentration (reduction in controls from 6.64, 45.39, and 86.39 ng/mL to 1.24, 12.35, and 34.36 ng/mL, respectively). Hence, the synthetic 1,3,5-triazine derivative 4f exhibited promising antiproliferative activity in HCT-116 cells through apoptosis induction by targeting the EGFR and its downstream pathway.
Collapse
Affiliation(s)
- Ihab Shawish
- Department
of Chemistry, College of Science, King Saud
University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
- Department
of Math and Sciences, College of Humanities and Sciences, Prince Sultan University, P.O. Box 66833, Riyadh 11586, Saudi Arabia
| | - Assem Barakat
- Department
of Chemistry, College of Science, King Saud
University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
| | - Ali Aldalbahi
- Department
of Chemistry, College of Science, King Saud
University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
| | - Azizah M. Malebari
- Department
of Pharmaceutical Chemistry, College of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - Mohamed S. Nafie
- Department
of Chemistry, Faculty of Science, Suez Canal
University, Ismailia 41522, Egypt
| | - Adnan A. Bekhit
- Department
of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
- Pharmacy
Program, Allied Health Department, College of Health and Sport Sciences, University of Bahrain, Zallaq, Kingdom of Bahrain
| | - Amgad Albohy
- Department
of Pharmaceutical Chemistry, Faculty of Pharmacy, The British University in Egypt (BUE), El-Sherouk City, Suez Desert Road, Cairo 11837, Egypt
- The Center
for Drug Research and Development (CDRD), Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo 11837, Egypt
| | - Alamgir Khan
- H.E.J. Research
Institute of Chemistry, International Center for Chemical and Biological
Sciences, University of Karachi, Karachi 75270, Pakistan
| | - Zaheer Ul-Haq
- H.E.J. Research
Institute of Chemistry, International Center for Chemical and Biological
Sciences, University of Karachi, Karachi 75270, Pakistan
- Dr. Panjwani
Center for Molecular Medicine and Drug Research, International Center
for Chemical and Biological Sciences, University
of Karachi, Karachi 75270, Pakistan
| | - Matti Haukka
- Department
of Chemistry, University of Jyväskylä, P.O. Box 35, FI-40014 Jyväskylä, Finland
| | - Beatriz G. de la Torre
- KwaZulu-Natal
Research Innovation and Sequencing Platform (KRISP), School of Laboratory
Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa
- Peptide
Science Laboratory, School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4000, South
Africa
| | - Fernando Albericio
- Peptide
Science Laboratory, School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4000, South
Africa
- Institute
for Advanced Chemistry of Catalonia (IQAC−CSIC), 08034 Barcelona, Spain
- CIBER-BBN,
Networking Centre on Bioengineering, Biomaterials and Nanomedicine,
and Department of Organic Chemistry, University
of Barcelona, 08028 Barcelona, Spain
| | - Ayman El-Faham
- Department
of Chemistry, Faculty of Science, Alexandria
University, P.O. Box 426,
Ibrahimia, Alexandria 21321, Egypt
| |
Collapse
|
8
|
Shamshad H, Bakri R, Mirza AZ. Dihydrofolate reductase, thymidylate synthase, and serine hydroxy methyltransferase: successful targets against some infectious diseases. Mol Biol Rep 2022; 49:6659-6691. [PMID: 35253073 PMCID: PMC8898753 DOI: 10.1007/s11033-022-07266-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2021] [Accepted: 02/15/2022] [Indexed: 12/13/2022]
Abstract
Parasitic diseases have a serious impact on the world in terms of health and economics and are responsible for worldwide mortality and morbidity. The present review features the hybrid targeting involving three main enzymes for the treatment of different parasitic diseases. The enzymes Dihydrofolate reductase, thymidylate synthase, and Serine hydroxy methyltransferase play an essential role in the folate pathway. The present review focuses on these enzymes, which can be targeted against several diseases. It shed light on the past, present, and future of these targets, and it can be assessed that these targets can play a significant role against several infectious diseases. For combating viral and protozoal infectious diseases, these targets in combination should be addressed.
Collapse
Affiliation(s)
- Hina Shamshad
- Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
| | - Rowaida Bakri
- College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia
| | | |
Collapse
|
9
|
Kashyap A, Choudhury AAK, Saha A, Adhikari N, Ghosh SK, Shakya A, Patgiri SJ, Bhattacharyya DR, Singh UP, Bhat HR. Microwave-assisted synthesis of hybrid PABA-1,3,5-triazine derivatives as an antimalarial agent. J Biochem Mol Toxicol 2021; 35:e22860. [PMID: 34313355 DOI: 10.1002/jbt.22860] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Revised: 04/21/2021] [Accepted: 07/14/2021] [Indexed: 12/25/2022]
Abstract
The present manuscript deals with the development of novel p-aminobenzoic acid (PABA) associated 1,3,5-triazine derivatives as antimalarial agents. The molecules were developed via microwave-assisted synthesis and structures of compounds were ascertained via numerous analytical and spectroscopic techniques. The synthesized compounds were also subjected to ADMET analysis. In a docking analysis, the title compounds showed high and diverse binding affinities towards wild (-162.45 to -369.38 kcal/mol) and quadruple mutant (-165.36 to -209.47 kcal/mol) Pf-DHFR-TS via interacting with Phe58, Arg59, Ser111, Ile112, Phe116. The in vitro antimalarial activity suggested that compounds 4e, 4b, and 4h showed IC50 ranging from 4.18 to 8.66 μg/ml against the chloroquine-sensitive (3D7) strain of Plasmodium falciparum. Moreover, compounds 4g, 4b, 4e, and 4c showed IC50 ranging from 8.12 to 12.09 μg/ml against chloroquine-resistant (Dd2) strain. In conclusion, our study demonstrated the development of hybrid PABA substituted 1,3,5-triazines as a novel class of Pf-DHFR inhibitor for antimalarial drug discovery.
Collapse
Affiliation(s)
- Ankita Kashyap
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, India
| | - Ayesha A K Choudhury
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, India
| | - Ashmita Saha
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, India
| | - Nayana Adhikari
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, India
| | - Surajit K Ghosh
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, India
| | - Anshul Shakya
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, India
| | - Saurav J Patgiri
- Regional Medical Research Centre, Indian Council of Medical Research (ICMR), Dibrugarh, Assam, India
| | - Dibya R Bhattacharyya
- Regional Medical Research Centre, Indian Council of Medical Research (ICMR), Dibrugarh, Assam, India
| | - Udaya P Singh
- Drug Design and Discovery Laboratory, Department of Pharmaceutical Sciences, Sam Higginbottom University of Agriculture, Technology & Sciences, Allahabad, Uttar Pradesh, India
| | - Hans R Bhat
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, India
| |
Collapse
|
10
|
Panchal J, Jain S, Jain PK, Kishore D, Dwivedi J. Greener approach toward synthesis of biologically active
s
‐Triazine
(
TCT
) derivatives: A recent update. J Heterocycl Chem 2021. [DOI: 10.1002/jhet.4343] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- Jigar Panchal
- Department of Chemistry Banasthali Vidyapith Banasthali India
| | - Sonika Jain
- Department of Chemistry Banasthali Vidyapith Banasthali India
| | | | - Dharma Kishore
- Department of Chemistry Banasthali Vidyapith Banasthali India
| | - Jaya Dwivedi
- Department of Chemistry Banasthali Vidyapith Banasthali India
| |
Collapse
|
11
|
Soni JP, Joshi SV, Chemitikanti KS, Shankaraiah N. The Riveting Chemistry of Poly‐
aza
‐heterocycles Employing Microwave Technique: A Decade Review. European J Org Chem 2021. [DOI: 10.1002/ejoc.202001472] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- Jay Prakash Soni
- Department of Medicinal Chemistry National Institute of Pharmaceutical Education and Research (NIPER) Balanagar Hyderabad 500037 India
| | - Swanand Vinayak Joshi
- Department of Medicinal Chemistry National Institute of Pharmaceutical Education and Research (NIPER) Balanagar Hyderabad 500037 India
| | - Krishna Sowjanya Chemitikanti
- Department of Medicinal Chemistry National Institute of Pharmaceutical Education and Research (NIPER) Balanagar Hyderabad 500037 India
| | - Nagula Shankaraiah
- Department of Medicinal Chemistry National Institute of Pharmaceutical Education and Research (NIPER) Balanagar Hyderabad 500037 India
| |
Collapse
|
12
|
Design and development of 1,3,5-triazine-thiadiazole hybrids as potent adenosine A 2A receptor (A 2AR) antagonist for benefit in Parkinson's disease. Neurosci Lett 2020; 735:135222. [PMID: 32619652 DOI: 10.1016/j.neulet.2020.135222] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Revised: 06/25/2020] [Accepted: 06/27/2020] [Indexed: 12/20/2022]
Abstract
Various studies showed adenosine A2A receptors (A2ARs) antagonists have profound therapeutic efficacy in Parkinsons Disease (PD) by improving dopamine transmission, thus being active in reversing motor deficits and extrapyramidal symptoms related to the disease. Therefore, in the presents study, we have showed the development of novel 1,3,5-triazine-thiadiazole derivative as potent A2ARs antagonist. In the radioligand binding assay, these molecules showed excellent binding affinity with A2AR compared to A1R, with significant selectivity. Results suggest, compound 7e as most potent antagonist of A2AR among the tested series. In docking analysis with A2AR protein model, compound 7e found to be deeply buried into the cavity of receptor lined via making numerous interatomic contacts with His264, Tyr271, His278, Glu169, Ala63, Val84, Ile274, Met270, Phe169. Collectively, our study demonstrated 1,3,5-triazine-thiadiazole hybrid as a highly effective scaffold for the design of new A2A antagonists.
Collapse
|